Peer-reviewed veterinary case report
Intranasal vaccine protects cats from similar feline calicivirus
By Sato, Hiroaki et al.·Published in The Journal of general virology·2017·Kyoto Biken Laboratories, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intranasal immunization with inactivated feline calicivirus particles confers robust protection against homologous virus and suppression against heterologous virus in cats.
- Species:
- cat
Plain-English summary
A group of cats received an experimental intranasal vaccine to protect against feline calicivirus (FCV), a common virus that can cause respiratory issues and oral ulcers. The cats were then exposed to both the same strain of the virus and a different strain. While the vaccine effectively protected against the same strain, it didn't fully protect against the different strain. However, the cats that received the intranasal vaccine showed milder symptoms and a quicker immune response compared to those that received the vaccine through injection. This suggests that the intranasal method may be a better option for vaccinating against FCV.
People also search for: cat calicivirus vaccine · feline calicivirus symptoms · intranasal vaccine for cats
Abstract
The protective efficacy of intranasal (IN) administration of inactivated feline calicivirus (FCV) vaccine against homologous or heterologous FCV infection was investigated. Groups of cats immunized with the experimental inactivated, non-adjuvanted FCV vaccine via either the IN or subcutaneous (SC) route were exposed to homologous or highly heterologous FCV. Both the IN and SC immunization protocols established robust protection against homologous FCV infection. Although neither immunization regimen conferred protection against the heterologous strain, clinical scores and virus titres of oral swabs were lower in cats in the IN group compared to those in the SC group, accompanying a faster neutralizing antibody response against the heterologous virus in cats in the IN group. The IN group secreted more IgA specific to FCV proteins in oral washes (lavage fluids from the oral cavity) than the SC group. IN immunization with an inactivated whole FCV particle, which protects cats from homologous virus exposure and shortens the period of heterologous virus shedding, may serve as a better platform for anti-FCV vaccine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28691897/